Saltar al contenido
Merck

O0391

Sigma-Aldrich

Olopatadine hydrochloride

≥98% (HPLC)

Sinónimos:

(11Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride, AL-4943A, KW-4679, Opatanol, Patanol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C21H23NO3·HCl
Número de CAS:
Peso molecular:
373.87
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

assay

≥98% (HPLC)

form

solid

solubility

H2O: ≥20 mg/mL

storage temp.

room temp

SMILES string

Cl.CN(C)CC\C=C1\c2ccccc2COc3ccc(CC(O)=O)cc13

InChI

1S/C21H23NO3.ClH/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24;/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24);1H/b18-8-;

InChI key

HVRLZEKDTUEKQH-NOILCQHBSA-N

Gene Information

human ... HRH1(3269)

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Olopatadine is a histamine H1 receptor antagonist and mast cell stabilizer. The low level of occupancy H1 receptors in the brain explains the low sedation effect of olopatidine. It is believed that olopatidine is a substrate for P-glycoprotein, which limits its brain penetration.

pictograms

Skull and crossbonesEnvironment

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Acute 1

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Yukari Okubo et al.
The Journal of dermatological treatment, 24(2), 153-160 (2011-08-04)
An increased dose of the prescribed drug or a change of the drug is recommended in the treatment for the patients with urticaria refractory to the standard dose of antihistamines. Efficacy and safety of doubling the dose of cetirizine were
Masahiko Shimura et al.
American journal of ophthalmology, 151(4), 697-702 (2011-01-25)
To evaluate the effectiveness of pre-seasonal treatment with topical olopatadine on the reduction of clinical symptoms of seasonal allergic conjunctivitis (SAC). Prospective interventional case series. Eleven patients with SAC received topical olopatadine in one eye at least two weeks before
Hiroyuki Kamei et al.
Archives of dermatological research, 304(4), 263-272 (2011-12-02)
Since most first-generation antihistamines have undesirable sedative effects on the central nervous systems (CNS), newer (second-generation) antihistamines have been developed to improve patients' quality of life. However, there are few reports that directly compare the antihistaminic efficacy and impairment of
Santa J Ono et al.
Drug design, development and therapy, 5, 77-84 (2011-02-23)
Antihistamines constitute the first line of therapy for allergic conjunctivitis, and are safe and effective in relieving the signs and symptoms of ocular allergy. Despite this, they are less effective than some other drugs in relieving delayed symptoms of allergic
Eli O Meltzer et al.
Allergy and asthma proceedings, 32(3), 213-220 (2011-04-12)
Allergic rhinitis (AR) is highly prevalent in children. Olopatadine, 0.6% nasal spray (olopatadine) is approved for the relief of seasonal allergic rhinitis (SAR) symptoms in children 6 years of age and older. The objective of this study is to provide

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico